<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598036</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VCS-2017-03</org_study_id>
    <nct_id>NCT03598036</nct_id>
  </id_info>
  <brief_title>Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis</brief_title>
  <acronym>AURONA™</acronym>
  <official_title>An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission&#xD;
      of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the current study to assess the efficacy of voclosporin in achieving complete or&#xD;
      partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental&#xD;
      glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin&#xD;
      over 24 weeks in subjects with FSGS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate&#xD;
  </why_stopped>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Remission of Proteinuria</measure>
    <time_frame>24 weeks</time_frame>
    <description>Complete remission OR Partial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Complete Remission or Partial Remission of Proteinuria</measure>
    <time_frame>Weeks 8 and 12</time_frame>
    <description>Complete remission or partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Complete Remission of Proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Complete remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Reduction of Proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Reduction of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Partial Remission of Proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Complete or Partial Remission of Proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Complete OR partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Complete Remission of Proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Complete remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Partial Remission of Proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Reduced Urine Protein Creatinine Ratio (UPCR)</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Duration of reduced Urine Protein Creatinine Ratio (UPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Protein Creatinine Ratio (UPCR)</measure>
    <time_frame>Weeks 2,4,8,12,18,24</time_frame>
    <description>Change from baseline in Urine Protein Creatinine Ratio (UPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Weeks 2,4,8,12,18,24</time_frame>
    <description>Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Week 24 to Week 26</time_frame>
    <description>Increase in Estimated Glomerular Filtration Rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Protein Creatinine Ratio (UPCR)</measure>
    <time_frame>Week 24 and Week 26</time_frame>
    <description>Change in Urine Protein Creatinine Ratio (UPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Week 24 and Week 26</time_frame>
    <description>Change in estimated Glomerular Filtration Rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Weeks 2,4,8,12,18,24</time_frame>
    <description>Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (Treatment-Emergent Adverse Events)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence and number of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Biopsy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1:&#xD;
Maximum dose of 3 capsules (7.9mg) BID&#xD;
Cohort 2&#xD;
Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin</intervention_name>
    <description>Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).&#xD;
The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1.</description>
    <arm_group_label>Voclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary FSGS diagnosed by renal biopsy.&#xD;
&#xD;
          2. Urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≤3.2 g/dL and can be&#xD;
             immunosuppressant treatment-naïve, or receiving treatment with steroids.&#xD;
&#xD;
          3. Stable proteinuria, renal function, and BP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical or histologic evidence of secondary FSGS.&#xD;
&#xD;
          2. Histologic evidence of collapsing variant FSGS.&#xD;
&#xD;
          3. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)&#xD;
             equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45&#xD;
             mL/minute/1.73 m2 at last qualifying assessment.&#xD;
&#xD;
          4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected&#xD;
             to require dialysis during the study period.&#xD;
&#xD;
          5. Current or medical history of:&#xD;
&#xD;
               -  Congenital or acquired immunodeficiency.&#xD;
&#xD;
               -  In the opinion of the Investigator, clinically significant drug or alcohol abuse&#xD;
                  within 2 years prior to screening.&#xD;
&#xD;
               -  Malignancy within 5 years of screening, with the exception of basal and squamous&#xD;
                  cell carcinomas treated by complete excision.&#xD;
&#xD;
               -  Current or past lymphoproliferative disease or previous total lymphoid&#xD;
                  irradiation.&#xD;
&#xD;
               -  Severe viral infection within 3 months of screening, or known HIV infection.&#xD;
                  Severe viral infection is defined as active disease requiring antiviral therapy.&#xD;
&#xD;
               -  Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking&#xD;
                  prophylaxis with isoniazid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Centre</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Centre</name>
      <address>
        <city>Santiago De Los Caballeros</city>
        <zip>51000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.</citation>
    <PMID>24330024</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8.</citation>
    <PMID>23996158</PMID>
  </reference>
  <reference>
    <citation>Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4.</citation>
    <PMID>23736966</PMID>
  </reference>
  <reference>
    <citation>Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.</citation>
    <PMID>21943027</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <results_first_submitted>May 17, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Protocol v1.0</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03598036/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Protocol v2.0 (Amendment 1)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03598036/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Protocol v3.0 (Amendment 2)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03598036/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Protocol v4.0 (Amendment 3)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03598036/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Voclosporin Cohort 1</title>
          <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7 mg total) twice daily</description>
        </group>
        <group group_id="P2">
          <title>Voclosporin Cohort 2</title>
          <description>Trial ended prematurely before any patients were enrolled into Cohort 2&#xD;
Cohort 2:&#xD;
When Cohort 1 have completed 12 weeks of treatment with voclosporin, the top line efficacy and safety data will be analyzed to determine the dose level for Cohort 2. The selected dose may be higher or lower than 23.7 mg twice daily.&#xD;
The maximum dose possible for Cohort 2 will be 39.5 mg (5 capsules) twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0">Trial ended prematurely before any patients were enrolled into Cohort 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 1: 7.9 mg Twice Daily</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 2: 15.9 mg Twice Daily</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Weeks 3 - 24: 23.7 mg Twice Daily</title>
              <participants_list>
                <participants group_id="P1" count="5">1 subject withdrew at Week 12</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Trial ended prematurely before any patients were enrolled into Cohort 2</population>
      <group_list>
        <group group_id="B1">
          <title>Voclosporin Cohort 1</title>
          <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7 mg total) twice daily</description>
        </group>
        <group group_id="B2">
          <title>Voclosporin Cohort 2</title>
          <description>Trial ended prematurely before any patients were enrolled into Cohort 2&#xD;
Cohort 2:&#xD;
When Cohort 1 have completed 12 weeks of treatment with voclosporin, the top line efficacy and safety data will be analyzed to determine the dose level for Cohort 2. The selected dose may be higher or lower than 23.7 mg twice daily.&#xD;
The maximum dose possible for Cohort 2 will be 39.5 mg (5 capsules) twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="20.71"/>
                    <measurement group_id="B3" value="36.2" spread="20.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Remission of Proteinuria</title>
        <description>Complete remission OR Partial remission</description>
        <time_frame>24 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7 mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Remission of Proteinuria</title>
          <description>Complete remission OR Partial remission</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Complete Remission or Partial Remission of Proteinuria</title>
        <description>Complete remission or partial remission of proteinuria</description>
        <time_frame>Weeks 8 and 12</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Complete Remission or Partial Remission of Proteinuria</title>
          <description>Complete remission or partial remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Complete Remission of Proteinuria</title>
        <description>Complete remission of proteinuria</description>
        <time_frame>Weeks 8, 12, and 24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Complete Remission of Proteinuria</title>
          <description>Complete remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Reduction of Proteinuria</title>
        <description>Reduction of proteinuria</description>
        <time_frame>Weeks 8, 12, and 24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Reduction of Proteinuria</title>
          <description>Reduction of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Partial Remission of Proteinuria</title>
        <description>Partial remission of proteinuria</description>
        <time_frame>Weeks 8, 12, and 24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Partial Remission of Proteinuria</title>
          <description>Partial remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Complete or Partial Remission of Proteinuria</title>
        <description>Complete OR partial remission of proteinuria</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Complete or Partial Remission of Proteinuria</title>
          <description>Complete OR partial remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Complete Remission of Proteinuria</title>
        <description>Complete remission of proteinuria</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Complete Remission of Proteinuria</title>
          <description>Complete remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Partial Remission of Proteinuria</title>
        <description>Partial remission of proteinuria</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Partial Remission of Proteinuria</title>
          <description>Partial remission of proteinuria</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline</title>
        <description>50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline</title>
          <description>50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Reduced Urine Protein Creatinine Ratio (UPCR)</title>
        <description>Duration of reduced Urine Protein Creatinine Ratio (UPCR)</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Reduced Urine Protein Creatinine Ratio (UPCR)</title>
          <description>Duration of reduced Urine Protein Creatinine Ratio (UPCR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Protein Creatinine Ratio (UPCR)</title>
        <description>Change from baseline in Urine Protein Creatinine Ratio (UPCR)</description>
        <time_frame>Weeks 2,4,8,12,18,24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Protein Creatinine Ratio (UPCR)</title>
          <description>Change from baseline in Urine Protein Creatinine Ratio (UPCR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula</description>
        <time_frame>Weeks 2,4,8,12,18,24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Increase in Estimated Glomerular Filtration Rate (eGFR)</description>
        <time_frame>Week 24 to Week 26</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Increase in Estimated Glomerular Filtration Rate (eGFR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine Protein Creatinine Ratio (UPCR)</title>
        <description>Change in Urine Protein Creatinine Ratio (UPCR)</description>
        <time_frame>Week 24 and Week 26</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Protein Creatinine Ratio (UPCR)</title>
          <description>Change in Urine Protein Creatinine Ratio (UPCR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Change in estimated Glomerular Filtration Rate (eGFR)</description>
        <time_frame>Week 24 and Week 26</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Change in estimated Glomerular Filtration Rate (eGFR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)</title>
        <description>Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)</description>
        <time_frame>Weeks 2,4,8,12,18,24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)</title>
          <description>Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessments</title>
        <description>Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures</description>
        <time_frame>Week 24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessments</title>
          <description>Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessments</title>
        <description>Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)</description>
        <time_frame>Week 24</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessments</title>
          <description>Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability (Treatment-Emergent Adverse Events)</title>
        <description>Incidence and number of treatment-emergent adverse events</description>
        <time_frame>24 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability (Treatment-Emergent Adverse Events)</title>
          <description>Incidence and number of treatment-emergent adverse events</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Biopsy</title>
        <description>Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients</description>
        <time_frame>24 weeks</time_frame>
        <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Voclosporin Cohort 1</title>
            <description>Cohort 1:&#xD;
Maximum dose of 3 capsules voclosporin (23.7mg total) twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Biopsy</title>
          <description>Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients</description>
          <population>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial. The primary and secondary endpoints were not assessed due to insufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Week 26</time_frame>
      <desc>Trial ended prematurely before any patients were enrolled into Cohort 2</desc>
      <group_list>
        <group group_id="E1">
          <title>Voclosporin Cohort 1: Week 1</title>
          <description>Cohort 1: Week 1 7.9 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Voclosporin Cohort 1: Week 2</title>
          <description>Cohort 1: Week 2 15.9 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Voclosporin Cohort 1: Weeks 3-24</title>
          <description>Cohort 1: Weeks 3-24 23.7 mg twice daily</description>
        </group>
        <group group_id="E4">
          <title>Voclosporin Cohort 2</title>
          <description>Trial ended prematurely before any patients were enrolled into Cohort 2&#xD;
Cohort 2:&#xD;
When Cohort 1 have completed 12 weeks of treatment with voclosporin, the top line efficacy and safety data will be analyzed to determine the dose level for Cohort 2. The selected dose may be higher or lower than 23.7 mg twice daily.&#xD;
The maximum dose possible for Cohort 2 will be 39.5 mg (5 capsules) twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Support</name_or_title>
      <organization>Aurinia Pharmaceuticals Inc.</organization>
      <phone>1 (250) 744-2487</phone>
      <email>clinicaltrials@auriniapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

